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Abstract
Golden Retriever Muscular Dystrophy (GRMD) is a dystrophin-deficient canine model genetically homologous to Duchenne
Muscular Dystrophy (DMD) in humans. Muscular fibrosis secondary to cycles of degeneration/regeneration of dystrophic
muscle tissue and muscular weakness leads to biomechanical adaptation that impairs the quality of gait. Physical therapy
(PT) is one of the supportive therapies available for DMD, however, motor PT approaches have controversial
recommendations and there is no consensus regarding the type and intensity of physical therapy. In this study we
investigated the effect of physical therapy on gait biomechanics and muscular collagen deposition types I and III in
dystrophin-deficient dogs. Two dystrophic dogs (treated dogs-TD) underwent a PT protocol of active walking exercise, 36/
week, 40 minutes/day, 12 weeks. Two dystrophic control dogs (CD) maintained their routine of activities of daily living. At t0
(pre) and t1 (post-physical therapy), collagen type I and III were assessed by immunohistochemistry and gait biomechanics
were analyzed. Angular displacement of shoulder, elbow, carpal, hip, stifle and tarsal joint and vertical (Fy), mediolateral (Fz)
and craniocaudal (Fx) ground reaction forces (GRF) were assessed. Wilcoxon test was used to verify the difference of
biomechanical variables between t0 and t1, considering p,.05. Type I collagen of endomysium suffered the influence of PT,
as well as gait speed that had decreased from t0 to t1 (p,.000). The PT protocol employed accelerates morphological
alterations on dystrophic muscle and promotes a slower velocity of gait. Control dogs which maintained their routine of
activities of daily living seem to have found a better balance between movement and preservation of motor function.
Citation: Gaiad TP, Araujo KPC, Serra˜o JC, Miglino MA, Ambro´sio CE (2014) Motor Physical Therapy Affects Muscle Collagen Type I and Decreases Gait Speed in
Dystrophin-Deficient Dogs. PLoS ONE 9(4): e93500. doi:10.1371/journal.pone.0093500
Editor: Johnny Huard, University of Pittsburgh, United States of America
Received July 16, 2013; Accepted March 7, 2014; Published April 8, 2014
Copyright:  2014 Gaiad et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was supported by FAPESP (Fundac¸a˜o de Amparo a` pesquisa do Estado de Sa˜o Paulo) process nu06/61561-6. The funders had no role in
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: Coauthor Carlos Eduardo Ambrosio is a PLOS ONE Editorial Board member and confirms that this does not alter his adherence to all the
PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
* E-mail: ceambrosio@usp.br
Introduction
Animal models for Duchenne Muscular Dystrophy (DMD)
studies are used to attest the viability of therapies that aims to
reduce the progression of this disease in humans. GRMD (Golden
Retriever Muscular Dystrophy) is a dystrophin-deficient canine
model that has been widely studied [1] since it presents muscle
abnormalities that are closest to the ones seen in humans:
increased creatine kinase activity, muscle hypotrophy, contrac-
tures, degeneration, endomysial and perimysial fibrosis [2,3]. This
model also presents repeated cycles of muscular necrosis and
regeneration, muscle wasting, postural abnormalities and respira-
tory or heart failure, as seen in DMD patients [4].
Since the coding sequence of the dystrophin gene was
discovered in 1987 [5], no treatment has been found to stop
DMD progression. To improve quality of life and prevent
complications, patients have access to supportive therapies such
as physical therapy. Although these therapies cannot cure DMD,
they should be well investigated as they intend to lead these
patients to a better quality of life and to decrease the complications
of DMD [6].
Physical therapy (PT) has been used to reduce muscular, cardiac
and vascular abnormalities which develop in association with
muscle strength loss [7]. The main objective of PT is the
prevention of hypotrophy associated with contractures and bone
deformities [8]. However, PT approaches have yielded controver-
sial recommendations [9] and there is no consensus regarding the
type and intensity of PT [10].
Muscular fibrosis is a morphological feature considered
secondary to cycles of degeneration and regeneration of dystrophic
muscle tissue [4]. Endomysial fibrosis is characteristic of the
GRMD model, human patients and diaphragm muscle of mdx
mouse [11], and its analysis on dystrophic muscle can bring
important information about tissue adaptation. Collagen is the
main component of muscle fibrosis and the types I, III and IV are
the most studied types on muscular dystrophies [12]. In a previous
study, we have found great amount of collagen types I and III in
the endomysium and perymisium of GRMD muscle [7]. The
study of localization and ratio of these types of collagen during a
PT intervention can elucidate its effects on dystrophic muscle
adaptation to movement.
Muscular weakness due progressive lesions in dystrophin-
deficient muscular fibers leads to biomechanical adaptation and
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limited range of motion that impair the quality of gait. As well as
DMD humans, GRMD dogs develop alterations in gait pattern.
On GRMD model alterations can be visually observed from the
fourth months of life of these animals [2]. Some studies on DMD
patients have been conducted in early stage patients when clinical
and functional evaluation do not allow to quantify initial walking
worsening or to identify the changes adopted to compensate for
muscle weakness [13,14]. According to these authors, instrument-
ed gait analysis are more sensitive than other clinical or functional
assessments to verify early modifications on gait pattern of DMD
humans [13] and opens new perspectives for the objective
assessment of efficacy of the new therapies associated with
Duchenne muscular dystrophy [14].
Previous studies with GRMD dogs have shown, mainly, the
morphological and molecular features of dystrophic muscle.
Assessment of muscle function was performed by functional scales
[15,16,17] and they are important to detail phenotypic variability
and progression of the disease in GRMD dogs, but they do not
have the sensibility to attest small changes during the progression
of the disease. Kinematic analysis of pelvic limbs joints have
already been studied in this model by Barthe´le´my et al. [18] using
accelerometer in adult animals, Marsh et al. [19] that have
quantified the two-dimensional kinematics of gait during over-
ground walking at a self-selected speed at the stifle (knee) and hock
(ankle) joints. Recently, Barthe´le´my et al. [20] have described
longitudinal ambulatory measurements of dystrophin-deficient
dogs during growth and disease progression using an ambulatory
gait analyzer (3D-accelerometers). In 2013, Shin et al. [21] have
quantify dog gait (stride length and speed), joint angle and limb
mobility (for both forelimb and hind limb), and spontaneous
activity at night using a video recording system. The group of
Barthe´le´my et al. [22] have used the accelerometer tool to assess
the effects of an immunosuppressive therapy on GRMD dogs.
Until now, we have not seen the dynamics of gait using a force
plate describing the gait of dystrophin-deficient dogs. We aimed
here to investigate the effect of an active walking exercise protocol
in dystrophin-deficient dogs using morphological analyses and
kinematic and dynamic quantitative assessment tools.
Methods and Ethics Statement
Four dystrophic dogs were selected from GRMD kennel –
Brazil. Because management of a GRMD model colony is
expensive, laborious, and this disease is rare, we have chosen to
study a reduced number of animals which had in common the
same age. The use of dystrophic animals of the same age decreases
phenotypic variability that is a usual feature of this model [2,15].
Research was approved by the Bioethics Committee of the School
of Veterinary and Animal Science of the University of Sa˜o Paulo,
protocol nu 1030/2006. DNA analysis on blood samples from
these dogs were done to confirm the presence of muscular
dystrophy. Prior to data collection, all dogs had a complete
clinical, orthopedic and neurologic assessment to ensure that there
were no underlying conditions that would influence gait.
Study design
Assessments were performed at time zero (t0) and time one (t1).
At t0, animals were 5 months old (mean height: 43 cm 61.15;
body mass: 12.6 kg 61.9). During 12 weeks, two GRMD animals
underwent exercise training and were named TD (Treated dog 1 –
TD1 and Treated dog 2 – TD2). Other 2 dogs had maintained
their routine of activities of daily living and were named CD
(Control dog 1 - CD1 and Control dog 2 - CD2). An open-air
enclosure of 20 m2 was available for all GRMD dogs during the
day, while at night, the same dogs were kept in closed pens of 1 to
3 m2. Time spent in these places during day and night was the
same for all GRMD dogs, excepted when TD were undergoing
exercise training. Daily activities consisted of feeding, cleaning
care and clinical analysis. Evaluations at t1 were performed after
these 12 weeks when animals were 9 months old (mean height:
51.160.85; body mass: 17.862.24).
Intervention
Type, frequency and duration of the physical therapy protocol
were selected from published recommendations for DMD patients
[23,24,25,26] and adapted to GRMD dogs. These publications
bring indicated modalities of exercise based on previously
investigation on animal models for DMD and on human studies
(See Table S1). Motor physical therapy (PT) sessions were
performed 3 times a week, with a resting day between PT
sessions, for 40 minutes/day over 12 weeks. An area with
3665 meters was constructed for PT session. PT sessions consisted
of walking exercise with velocity defined as at least 10% more than
their walk velocity. During PT sessions, velocity was recorded
using a chronometer and dogs were allowed to rest between each
circuit, aiming to avoid fatigue. The velocity was archived using
the chronometer and calculated based on distance covered.
Velocity had been recorded during the walking period and
stopped during the rest time. TD left the Zero Point and walked 8
times the 36 meters area. Each circuit (36 meters) was considered
valid if animals had completed it and its minimal exercise velocity
established. Morphological and biomechanics of gait data from
GRMD dogs were collected at t0 and t1.
Immunohistochemistry (IHC)
Muscle fragments were collected from biceps femoralis of each dog
for morphological analysis. To avoid any loss of motor function, a
single muscle was chosen to represent the pelvic limb. Hind limbs
are considered more affected in the canine dystrophy model [27]
and biceps femoralis was choosen to represent pelvic limb once it is a
large and superficial muscle that provides easy access during
muscle collection. An open biopsy was performed with the
collection of a 1 cm2 fragment from the middle portion of the
muscle. Dogs were submitted to an anesthetic protocol previously
approved by the Ethics Committee. In order to avoid scar fibrosis
after the first biopsy, the second one was performed at least
2 centimeters away from the scar tissue. Muscle fragments were
fixed in Paraformaldehyde solution at 4%, treated with increasing
ethanol series (70 to 100%) to dehydration and xylene for clearing.
Fragments were embedded in paraffin and sections of 5 mm were
obtained.
Primary antibodies against collagen (anti-mouse) types I and III
(Calbiochem) (1:500 and 1:750 dilution) were applied on muscle
sections, separately. After being washed three times in phosphate-
buffered saline (PBS), the sections were incubated for 45 minutes
with biotinylated antibody (Dako Ltd.) in a damp chamber at
room temperature. After three more rinses in PBS, streptavidin
was applied for 45 minutes. The sections were washed with PBS
and covered with 3,39-diaminobenzidine tetrahydrochloride
(DAB) for 1 to 2 minutes. The primary antibody was omitted in
control sections. Photomicrographs were taken using an optical
microscope (Axioscope, Zeiss) equipped with an Olympus BX 60
camera.
Gait analysis
Data was collected at the Biomechanics Laboratory of the
School of Physical Education and Sports of the University of Sa˜o
Paulo. Video records of the gait and Ground Reaction Forces
Motor Physical Therapy in GRMD Dogs
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(GRF) collection were synchronized collected. Aiming that animals
presented a naturally way of walk during data collection, GRMD
dogs had gone to the Biomechanics Laboratory for 3 times, for one
hour, during one week to adaptation to the environment prior to
t0 collection.
Video collection
Digital video (Panasonic PV-GS50S model) of sagittal plane of
motion was collected during over-ground walking at the dog’s self-
selected pace with a single camera. The camera was positioned at
the transversal plane at the cranio-caudal direction at the right side
four meters away of the animals. Peak Motus System (Peak
Performance Technologies, Inc) has been used to register the
position and displacement of each body segment during gait.
Thirteen retro-reflective markers (3M) were placed on anatom-
ical landmarks of the right limbs of the animals: 1.spina scapulae/
acromion; 2.humerus tuberculim majus; 3.humerus epicondylus lateralis;
4.ulna processus estyloideus; 5. Caput of ossa metacarpalia V; 6.crista
iliaca; 7. Feˆmur trochanter major; 8.femur condylus; 9. Malleulus lateralis
and 10. Caput ossa metatarsalia V. Three other landmarks were
placed at occipital crest, disto-medial aspect of the second contra-
lateral metatarsus and disto-medial aspect of the second contra-
lateral metacarpus (Figure 1). To facilitate marker placement,
trichotomy were made around each anatomical landmark and
glue was used to fix the markers of 1 to 2 cm2. Dogs were placed in
lateral recumbency to landmarkers attachment. Following marker
application, manual flexion and extension of the joints after
application of the markers was used to verify that the marker
positions were as close as possible to the joint centers.
Video processing
Each one of the trials were identified by three investigators as
valid or not. Trials were considered valid if dog walked over the
force plate without deviation from the plane. Only data from the
right side of the animals were considered for analysis. Six valid
trials of each one of the dogs at t0 and t1 were identified for further
analysis. A complete gait cycle was defined as starting the contact
with the fingers of the right forelimb and ending with the
ipsilateral hindlimb contact. A rest period after each one of the
cycles was provided, if necessary, for all GRMD dogs. Dogs were
allowed to rest for a maximal time of 3 minutes between each
cycle. Digitizing software Peak Motus System and MATLAB (The
MathWorks, Natick, MA) programs were used to calculate joint
angles of the shoulder, elbow, carpus, hip, stifle and tarsus. Raw x–
y co-ordinate data were filtered using a Butterworth filter with a
cutoff frequency of 4 Hz. Each gait cycle was normalized in time
(100% of gait cycle) and body mass (N/kg).
Dynamics of gait
A quartz crystal piezoelectric Kistler force plate (FP) (Kistler
type 9287, Kistler Instrumente AG, Winterthur, Switzerland) was
used together with the Kistler 9865B charge amplifiers. The FP
(60690 cm) was mounted flush with the surface. The middle 2 m
of the runway was bordered behind by a 50-cm-high fence at the
left side of the dogs to guide the dogs over the FP. The sampling
rate was 100 Hz, and recordings were saved for further processing.
Mediolateral (Fz), cranio-caudal (Fx), and vertical (Fy) forces were
analyzed. Fy was calibrated with a standard weight before each
recording session.
Statistical analysis
Statistical analysis was performed using software Biostat (Biostat
2009 version 5.3.5 for Windows). Kolmorov-Smirnov test was
used to determine if mean data of angular displacement, GRF and
velocity were normally distributed. Data was not normally
distributed and Wilcoxon test was applied to attest individually
difference between t0 and t1 of each one of the variables. Each dog
had its all data at t0 compared to all data at t1 for each one of the
studied variables.. All data are expressed as mean6SD. The level
of significance was set at p,.05.
Results
Immunohistochemistry analysis at t0 has shown that collagen I
is present in greater amount at perymisium of TD and CD than
healthy dogs. At t1, type I collagen was also observed at
endomysium of both TD muscle (Figure 2) and no positive signal
at CD. Collagen type III was observed at perymisium and
endomysium of TD and CD from t0, and did not change between
t0 and t1 (Figure 3).
Velocity of gait of TD1 and TD2 have been slower at t1 than at
t0 (p,0.000). Data of mean velocity of gait of each one of the dogs
at t0 and t1 are shown at Figure 4 and detailed on Table 1. CD1
and CD2 have maintained their gait speed between t0 and t1
(Figure 4). Results of angular displacement (Figures 5 and 6) and
GRF (Figure 7) were described individually for each joint and dogs
at t0 and t1. Data are presented as average of six trials of each dog.
Data of CD at t1 have been shown to illustrate the progression of
dystrophin deficiency without exercise intervention.
Figure 1. Location of anatomical landmarks. 1.spina scapulae/acromion; 2.humerus tuberculim majus; 3.humerus epicondylus lateralis; 4.ulna
processus estyloideus; 5. caput of ossa metacarpalia V; 6.crista iliaca; 7. femur trochanter major; 8.femur condylus; 9. malleulus lateralis and 10. caput
ossa metatarsalia V. 11. occipital crest, 12. distomedial aspect of the second contra-lateral metatarsus and 13. disto-medial aspect of the second
contra-lateral metacarpus.
doi:10.1371/journal.pone.0093500.g001
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Control Dog 1 (CD1)
All joints, with the exception of the shoulder (p = 0.215), have
changed from t0 to t1 (p,0.000). Hip, stifle and carpal joints have
presented an extended feature at t1. All GRF have changed from
t0 to t1 (p,0.000). Vertical force (Fz) of forelimb and braking
force (Fx2) increased from t0 to t1. CD1 has directed its hindlimb
force (Fy) to the medial direction at t1.
Control Dog 2 (CD2)
All joints, with the exception of the tarsus (p = 0.482), have
changed from t0 to t1 (p,0.000). Hip joint had an important
flexed feature at t1 when compared to t0. Vertical force values had
showed a significant increase in forelimb and hindlimb (p,0.000).
Fy and Fx had maintained its values between t0 and t1.
Treated Dog 1 (TD1)
All joints, with the exception of the carpal joint (p = 0.474), have
changed from t0 to t1 (p,0.000). At t1, TD1 walked with a hip
and elbow joint more flexed than at t0. On the other hand, stifle,
tarsus and shoulder have presented an extended feature during
walking. Fz and Fy have presented significant difference between
t0 and t1 (p,0.000). Vertical force (Fz) has increased from t0 to t1
and TD1 has directed its fore and hindlimb force (Fy) to the
medial direction.
Treated Dog 2 (TD2)
All joints of TD2 have changed from t0 to t1 (p,0.005). Hip
and carpal joints have presented an important decrease in their
ROM. At t1, these joints and the tarsal one have presented a
flexed feature during gait. Stifle joint had presented an extended
feature at t0. Vertical force (Fz) has increased from t0 to t1 and
TD2 has directed its hindlimb force (Fy) to the medial direction.
Discussion
PT of active walking exercise, three times per week, during
40 minutes, with intervals of rest aiming to avoid fatigue between
days and during exercise protocol, has decreased gait velocity and
increased the amount of collagen type I at endomysium of
dystrophic dogs. This same protocol has not influenced angular
displacement or GRF of dogs. Control dogs that have maintained
their daily life activities, e.g. postural changes independently with
the objective of getting water and food, with more hours of rest
during the week, have reached the balance between movements
without aggregate muscular damage.
Fibrosis is poorly understood on dystrophic muscle, but it seems
to be the consequence of inflammatory infiltrate due to muscular
damage [28]. Our results have shown that skeletal muscle of
GRMD animals at t0 have already presented increased muscular
Figure 2. Photomicrographs of immunohistochemical analysis
of collagen I in skeletal muscle. Positive immunostaining for
collagen type I (1:500) in biceps femoralis of healthy dog (A),
bar = 50 mm; control section, bar = 20 mm; CD at t0 (C) and t1 (D), TD
at t0 (E) and t1 (F), bar = 20 mm. perimysial fibrosis andc endomysial
fibrosis.
doi:10.1371/journal.pone.0093500.g002
Figure 3. Photomicrographs of immunohistochemical analysis
of collagen III in skeletal muscle. Positive immunostaining for
collagen type III (1:750) in biceps femoralis of healthy dog (A),
bar = 50 mm; control section, bar = 40 mm; CD at t0 (C) and t1 (D), TD
at t0 (E) and t1 (F), bar = 40 mm. perimysial fibrosis andc endomysial
fibrosis.
doi:10.1371/journal.pone.0093500.g003
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Figure 4. Data of gait speed of biomechanical analysis of TD1, TD2, CD1 and CD2 at t0 and t1. Values of TD1 and TD2 had presented
difference between t0 and t1, p,.05. * denote significant differences between t0 and t1, with p,.05.
doi:10.1371/journal.pone.0093500.g004
Figure 5. Mean and standard deviation of angular displacement (degrees) of hindlimbs. Hip, stifle and tarsus of TD1, TD2, CD1 and CD 2at
t0 and t1. Images with * denote significant differences between t0 and t1, with p,.05.
doi:10.1371/journal.pone.0093500.g005
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fibrosis deposition when compared to skeletal muscle of healthy
dogs [7]. At t0, collagen type I was immunolocalizated in a large
amount on perymisium of GRMD dogs and collagen type III was
immunolocalizated in large amount on endomysium of GRMD
dogs. This finding is in accordance with Cozzi et al. [29] and
Nguyen et al. [11] who have found the presence of increased
amount of fibrosis in early ages in dystrophic animals.
Collagen type I was influenced PT protocol and showed that
treated dogs presented higher muscular damage. A longitudinal
study with 25 human DMD patients have shown that among
histopathological features, myofiber atrophy, necrosis, and fatty
degeneration, only endomysial fibrosis was correlated with poor
functional outcome assessed by muscle strength and age of loss of
ambulation [30]. Collagen type I is characteristic of tissue with low
flexibility, e.g. tendon. The presence of this type of collagen at the
endomysium of dystrophic dogs who underwent walking exercise
protocol suggests a functional loss of these muscles.
Some authors suggest that the presence of collagen I in
muscular dystrophy inhibits muscle regeneration and support the
production of more muscular collagen [31]. Both mechanisms
affect strategies of treatment of DMD. Drugs or therapies able to
reduce fibrosis [28], such as antifibrotic therapy [32], have been
shown to be extremely promising to DMD patients by enhancing
the grip strength of pelvic limbs [33] or improving cardio
respiratory function [34].
Until now, we have seen few recent published papers that have
used biomechanical tools to asses gait variables of GRMD model.
Barthele´my et al. [18] have investigated the viability of acceler-
ometer as a quantitative tool to assess the gait of adult dystrophic
dogs. Marsh et al. [19] showed the kinematic features of pelvic
limbs from GRMD and healthy Golden Retriever females.
Another study of Barthe´le´my et al. [20] have followed ambulatory
measurements of gait abnormality in dystrophin-deficient dogs
from 2 to 9 months of age. Biomechanical assessment of gait, have
been used by Barthe´le´my et al. [22] to attest effects of an
immunossuppressive therapy. We have used kinematics and
dynamics of gait to attest the progression of four GRMD dogs
from 5 to 9 months of age with and without the presence of an
active walking protocol of physical therapy.
At t0, mean velocity of all dogs (0.63 m/s 60.27) were lower
than healthy dogs and considered a slow velocity of gait. Gait
speed is related to the time that limbs are in contact with the
ground while walking. Exercise could have provoked a decrease in
gait speed which means a deterioration of the gait function. Mean
velocity of dystrophic dogs in the study of Barthe´le´my et al. [18]
was 0.72 m/s, similar to the one observed in our dogs and
significantly lower than their control healthy dogs (3.97 m/s). The
gait of TD was more difficult to be performed than the gait of CD
at t1. It is possible that fatigue may be the reason behind this
reduced velocity, but studies to investigate muscular activation
using electromyography would be necessary to conclude about this
theory. PT played an important role in the decreasing velocity of
walking and it also clinically reflects in functional deterioration of
the muscle.
Figure 6. Mean and standard deviation of angular displacement (degrees) of forelimbs. Shoulder, elbow and carpus of TD1, TD2, CD1 and
CD2 at t0 and t1. Images with * denote significant differences between t0 and t1, with p,.05.
doi:10.1371/journal.pone.0093500.g006
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Elbow, hip and stifle joint showed significantly changes from t0
to t1 in all GRMD dogs, but PT has not influenced this data.
These changes reflect the natural progression of muscular
dystrophy. The stifle joint has shown an extended feature at t1
for all dogs, which are in accordance with visual assessment
previously described using a physical exam score [15]. The stifle
joint also presents less flexion movement at t1 compared to t0,
when maintaining an extended position. Marsh et al [19] have
studied six GRMD dogs and have found that they have presented
the stifle joint relatively more extended during walking. At the
hock joint, GRMD dogs displayed less range of motion and walked
with the joint relatively less flexed compared to controls.
Elbow and hip joints are also related to disease progression and
until now have been poorly studied [1,2] most likely due the
difficultly of visual observation of the proximal joint during gait.
According to Van der Walt [35], the hip is an important joint to
understand muscle skeletal alteration on quadrupeds because 30%
of orthopedic diseases affect pelvic limbs. Elbow, hip and stifle
joints should be better investigated on GRMD model.
Shoulder, carpal and tarsal joints have also changed from t0 to
t1 but these results were not common to all dystrophic dogs and
have not been influenced by PT. Figures 5 and 6 show that they
change in an individual manner. Once an animal has a quadruped
gait, changes in one joint alter the weight distribution on whole
body and cause adaptation in the other joints. It is possible that
each dog developed adaptations that are related to the extent and
distribution of their first signs of muscle skeletal alterations.
Vertical force (Fy) has increased from t0 to t1 in treated and
control dogs. Fy were already higher at t0 when compared to
healthy dogs [36]. It suggests that dystrophic dogs present an
overload to maintain their gait, most likely because of loss of
muscle mass and strength. Healthy dogs present increased Fy on
thoracic limbs when compared to pelvic limbs [36,37,38]. This
feature was also observed in our dystrophic dogs during the entire
study, which indicates that even with adaptations, GRMD still
Figure 7. Mean and standard deviation of GRF: vertical (Fy), craniocaudal (Fx) and mediolateral (Fz) of TD1, TD2, CD1 and CD2 at t0
and t1. Data in Newton (N) was normalized by body weight. The first 50% of the gait cycle represents forelimb contact and the last 50% represents
the hindlimb contact with the FP. Images with a * denote significant differences between t0 and t1, with p,.05.
doi:10.1371/journal.pone.0093500.g007
Table 1. Standard velocity of gait of each one of the dogs at
t0 and t1.
TD1 TD2 CD1 CD2
t0 mean 6 sd 0.85160.4 0.36860.09 0.42560.30 0.87960.32
min-max (m/s) 0.18–2.19 0.01–1.50 0.10–0.98 0.19–2.19
t1 mean 6 sd 0.59960.22 0.30260.12 0.41460.18 0.8760.31
min-max (m/s) 0.06–1.84 0.01–1.30 0.08–1.26 0.16–2.38
t0 = time zero (5 months old); t1 = time one (9 months old); sd = standart
deviation; min =minimal velocity; max =maximal velocity.
doi:10.1371/journal.pone.0093500.t001
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maintain this distribution of body weight between thoracic and
pelvic limbs.
Data of cranio-caudal force (Fx) indicate that propulsion force is
practically absent on these animals. Among quadrupeds, thoracic
limbs are responsible for braking force and pelvic ones are
responsible for the propulsion force during gait [36,39]. Decreased
values suggest loss of strength in these limbs [40]. On muscular
dystrophy, progressive loss of strength which initiates at pelvic
limbs leads propulsion force practically absent already at five
months of age. This feature was maintained along this study and
has not suffered influence of PT.
As DMD is a progressive disease which presents its first
symptoms early in life, physiotherapist can increase quality of life
of patients offering clarification and information to caregivers and
family. Moreover, it is possible to maintain muscle flexibility
stimulating active movements while playing with kids or stimulat-
ing the independent realization of activities of daily life.
Physiotherapists have great concern on motor objectives, but the
contradiction of movement versus motor function still needs
clarification. Physical therapy protocol of active walking exercise,
3 times per week, during 40 minutes, with intervals of rest, has
shown negatively effects on gait speed and has increased the
amount of muscular collagen of a type poorly flexible (type I) of
dystrophic dogs. Our results here described in association with the
literature allow us to suggest that DMD patients should be
encouraged to perform their daily activities independently and it
should be supported by adaptations in their environment and
individual limitations should be respected. Physiotherapists should
also take into account the expectation of patients and their interest
on therapy when planning therapies sessions. Nowadays, there is a
lot of research on drugs, cellular or gene therapies in pre-clinical
models of DMD [41,42] aiming to ameliorate or, at least, decrease
the velocity of progression of the disease. At the moment,
professionals involved in therapies of support, such as physiother-
apists, must offer the best that can be done for patients and their
families. Physiotherapists also must know how to measure the
movement that is possible, and find a balance between minimal
muscular lesion and the preservation of motor, mental and vital
function of patients.
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